Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.38 |
| ▸ | HRH1 | P35367 | 10/20 | 0.37 |
| ▸ | HRH2 | P25021 | 9/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093121 | 0.88 | HRH3 (0.40) | HRH3HRH1HRH2ALDH1A1HPGD | |
| SCHEMBL5965551 | 0.86 | HRH3 (0.48) | HRH3HRH1HRH2MEN1 | |
| SCHEMBL5965805 | 0.85 | ALDH1A1 (0.36) | HRH3HRH1HRH2ALDH1A1HPGD | |
| SCHEMBL5965684 | 0.83 | SIGMAR1 (0.42) | HRH3HRH1HRH2MEN1KMT2A | |
| SCHEMBL5965570 | 0.82 | HRH3 (0.39) | HRH3HRH1HRH2 | |
| SCHEMBL5965840 | 0.80 | PTGDR2 (0.42) | ALDH1A1HPGDMEN1PTGDR2KMT2A | |
| SCHEMBL5965575 | 0.78 | HRH2 (0.42) | HRH3HRH1HRH2ALDH1A1HPGD | |
| SCHEMBL5965401 | 0.78 | ALDH1A1 (0.36) | HRH3HRH1HRH2ALDH1A1HPGD | |
| SCHEMBL5965645 | 0.77 | HTR6 (0.41) | ALDH1A1MEN1KMT2A | |
| SCHEMBL5965510 | 0.77 | CHEK1 (0.33) | HRH3HRH1HRH2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012074-B2 | 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-03-14 | — | — | US | disclosed |
| US-20040023971-A1 | 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023971-A1 | 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias | KCNH1, KCNH2, RYR2 | HRH3 2774/4885HRH1 2038/4885HRH2 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.